Testing a new drug combined with standard treatment for advanced stomach tumors

Plain-English translation of NCT07406633 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called given together with imatinib, a drug that is already approved and used to treat gastrointestinal stromal tumors (a type of stomach cancer). The study wants to see if combining these two medications is safe, well-tolerated, and more effective than imatinib alone for people with advanced or spread-out disease.

While imatinib has helped many patients, some people's tumors stop responding to it or don't respond well from the start. This trial is exploring whether adding the new treatment can improve outcomes for patients facing advanced disease.

Do you qualify?

You likely qualify if…

you have been diagnosed with an advanced or metastatic gastrointestinal stromal tumor that cannot be removed by surgery
your tumor has been confirmed by tissue testing and has a specific genetic mutation (KIT or PDGFRA, with certain exceptions)
you have measurable disease that can be tracked on imaging scans
this is your first time receiving treatment for advanced disease (though you may have received imatinib before for early-stage disease if it was stopped more than a year ago)
you have adequate organ function and good overall health status to tolerate the treatment

You likely don't qualify if…

you have difficulty swallowing or a digestive condition that prevents your body from absorbing oral medications
you have had another active cancer diagnosed within the past 2 years
you are allergic or hypersensitive to KQB198 or imatinib
you are currently taking other active cancer treatments for a different malignancy

What participation looks like

As a participant, you would take both and imatinib by mouth as part of your first-line treatment for advanced disease. The study will monitor how well the combination works, track any side effects, and measure how your body processes these medications through blood tests and imaging scans. You would have regular clinic visits to assess your tumor response and overall health while on the treatment.

AI-generated summary from trial data · Jul 11, 2026 · Not medical advice

Trial locations(16 sites)

United States

USC Norris Comprehensive Cancer Center, Los Angeles, California

Mayo Clinic - Jacksonville, Jacksonville, Florida

Sylvester Comprehensive Cancer Center, Miami, Florida

Moffitt Cancer Center, Tampa, Florida

University of Chicago Medical Center, Chicago, Illinois